NCT06582706View on ClinicalTrials.gov

Nicotinic Acid for the Treatment of Alzheimer's Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

Placebo Comparator

a readily available inert placebo will be used

DRUG

Extended Release Niacin

500 mg

Trial Locations (1)

46202

RECRUITING

IU Health Neuroscience Center, Indianapolis

All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

Indiana University

OTHER